Cord blood transplant for children and young adults with blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Genetic & congenital, Immune system & allergy clinical trials.
This Phase 2 trial studies using a cord blood transplant after finding it is risky enough that standard treatment may not be sufficient. It may help certain children and young adults with specific leukemia, lymphoma, and some non-cancer blood/immune or inherited disorders who do not have a well-matched donor available in time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 years old or younger at the time you agree to join the study.
- You must not have a suitably matched related or unrelated donor available in the required time window.
- You have one of these specific conditions: certain high-risk AML or ALL, some other acute leukemias, certain MDS/MPD (not myelofibrosis), high-risk lymphoma, or listed inherited metabolic or non-malignant disorders.
- Your cancer/illness status must fit the trial’s timing category (for example, CR1/CR2, relapse/refractory with low blast counts, or specific MRD status).
- You must be well enough to tolerate transplant: activity score at least 70% and blood/organ tests within limits (liver, lung, heart, kidney).
- You must be eligible for cord blood donation matching: the cord blood unit must meet the HLA match and cell dose requirements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
This Phase 2 study tests using donated cord blood to treat certain adult blood cancers that are at high risk of coming back. It may help strengthen the body’s ability to rebuild blood and fight the cancer after intensive treatment.
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
This trial tests a second transplant using two donated umbilical cord blood units for people whose blood cancer returned after a first stem cell transplant. It aims to offer a potential cure for high-risk blood cancers.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.